ArticleScientific reports2026
CMS4 epithelial-intrinsic glycosyltransferase GALNT5 promotes tumor aggressiveness and correlates with poor survival in colorectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The "mesenchymal" consensus molecular subtype 4 (CMS4) of colorectal cancer (CRC) has the poorest prognosis and shows stromal activation and bulk epithelial-mesenchymal transition (EMT) signatures that largely reflect cancer-associated fibroblast-derived signals, obscuring tumor cell-intrinsic programs. Aberrant glycosylation drives EMT and metastasis, yet the glycosyltransferase landscape intrinsic to CMS4 tumor epithelium remains poorly defined because stromal signals dominate bulk transcriptomes. To overcome this confounding, we analyzed single-cell RNA-sequencing datasets to distinguish CMS4 tumor epithelial cells from CMS1-3 epithelial cells, normal epithelium, and stromal/immune populations. This identified a nine-gene glycosyltransferase signature uniquely upregulated in CMS4 tumor epithelium. Among these, GALNT5 showed consistent transcriptional induction during EMT in CRC cell lines. GALNT5 depletion suppressed proliferation, invasion, and migration, independent of overt changes in canonical EMT markers or AKT/ERK signaling. Immunohistochemical analysis of 431 resected CRC specimens confirmed that GALNT5 protein expression was restricted to cancer cells, particularly at the invasive front. High GALNT5 expression was associated with deeper invasion and advanced stage, and served as an independent prognostic factor for worse overall survival, notably within the microsatellite-stable subgroup. In conclusion, by leveraging single-cell transcriptomics, this study defines a CMS4 epithelial-intrinsic glycosylation program and highlights GALNT5 as a prognostic biomarker and therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.